Study of Genome-associated Mechanisms of Diabetic Nephropathy and Evaluation of Nephroprotective Therapy in Patients With Type 2 Diabetes Mellitus in the Kazakh Population

Plain-language summary

This study investigates genome-associated mechanisms of diabetic nephropathy and evaluates nephroprotective therapy in patients with type 2 diabetes mellitus in the Kazakh population. It examines markers such as glycation genes and beta 2 microglobulin, with the goal of developing more effective methods for early detection of diabetic nephropathy, a leading cause of chronic kidney disease. Enrollment is by invitation and open to consenting patients of Kazakh nationality, aged 18 to 65, with a verified diagnosis of type 2 diabetes.

The summary above is a plain-language rendering of the official record. The original English title is shown for reference.

Trial details

Phase

N/A

Status

Enrolling by invitation

Sponsor

Astana Medical University

Intervention

glycation genes, beta 2 microglobulin

Start date

7/19/2025

Estimated completion

12/30/2027

Countries

Kazakhstan

Related genes

Locations

• Astana, Kazakhstan

Eligibility criteria

Criteria are reproduced from the ClinicalTrials.gov record in the original English. Only the trial team can determine eligibility.

Inclusion Criteria:

* consent of the participant (signing the informed consent form);
* patients with a verified diagnosis of type 2 diabetes mellitus of Kazakh nationality
* age from 18 years to 65 years

Exclusion Criteria:

өage under 18 and over 65 years

* undiagnosed type 2 diabetes mellitus
* lack of informed consent
* pregnancy and lactation at the time of inclusion in the study;
* oncological disease at the time of inclusion in the study, decompensated concomitant somatic pathology.